CAR-T Referral Process: Insights from UCSF : Episode 8
Example of Successful Collaboration with a Referring Community Practice
Panelists discuss collaborating with community practices on CAR T-cell therapy for multiple myeloma through joint clinical trials, patient education programs, and shared data initiatives. These partnerships enhance treatment access, foster innovation, and improve patient outcomes across diverse settings.
EP: 1.Introduction and CAR-T Therapy in Earlier Lines of Treatment for R/R Multiple Myeloma
EP: 2.Decision Points for Using CAR T-Cell Therapy in Early Lines of Treatment
EP: 3.Second-Line Treatment for R/R Multiple Myeloma: Who Is the “Right Patient”?
EP: 4.Referral Process for CAR T-Cell Therapy: Initial Contact Through Patient Evaluation and Selection
EP: 5.CAR T-Cell Therapy: CAR T-Cell therapy Process and Bridging Therapy
EP: 6.Co-Management and Co-Monitoring of Patients Receiving CAR T-Cell Treatment: Transitions Between the Academic and Community Centers
EP: 7.Management of Adverse Events of Special Interest in Patients Receiving CAR -T-Cell Therapy for R/R Multiple Myeloma: Diarrhea, Guillain-Barrée Syndrome, Parkinson’s Disease, and Secondary Malignancies
Now Viewing
EP: 8.Example of Successful Collaboration with a Referring Community Practice
EP: 9.CAR T-Cell Therapy in Multiple Myeloma: Lessons Learned and Key Takeaways
Video content above is prompted by the following:
- Can you share any examples of successful collaborations between your academic center and community practices in the context of CAR T-cell therapy for multiple myeloma?
Recent Videos
Related Content
